

## Nivolumab

### Indication

Locally advanced or metastatic squamous non small cell lung cancer (NSCLC) after chemotherapy.

(NICE TA483)

Locally advanced or metastatic PD-L1 positive non squamous non small cell lung cancer (NSCLC) after chemotherapy

(NICE TA484)

If performance status  $\geq 2$  nivolumab should be used with caution after careful consideration of the potential benefit/risk.

### ICD-10 codes

Codes prefixed with C34.

### Regimen details

Day	Drug	Dose	Route
1	Nivolumab	240mg	IV infusion

### Cycle frequency

Every 14 days

### Number of cycles

Continued until disease progression or unacceptable toxicity to a maximum of 2 years uninterrupted treatment.

### Administration

Nivolumab may be administered without dilution or in sodium chloride 0.9% or glucose 5% at a concentration between 1-10mg/mL over 30 minutes. Nivolumab should be administered via an infusion set with an in-line sterile, non-pyrogenic, low protein binding filter (pore size 0.2 – 1.2 $\mu$ m).

Patients should be monitored (blood pressure, pulse and temperature) every 30 minutes during the infusion for infusion related reactions. For mild to moderate reactions, decrease the infusion rate and closely monitor. Premedication with paracetamol and chlorphenamine should be used for further doses. For severe infusion related reactions discontinue treatment.

### Pre-medication

Nil

### Emetogenicity

This regimen has low emetogenic potential

### Additional supportive medication

Loperamide if required.

## Extravasation

Nivolumab is neutral (Group 1)

### Investigations – pre first cycle

Investigation	Validity period (or as per local policy)
FBC	7 days
U+E (including creatinine)	7 days
LFT	7 days
Thyroid function	7 days
Calcium	7 days
Glucose	7 days
Cortisol	7 days

### Investigations – pre subsequent cycles

Investigation	Validity period (or as per local policy)
FBC	72 hours
U+E (including creatinine)	72 hours
LFT	72 hours
Calcium	As clinically indicated
Thyroid function*	72 hours
Glucose*	72 hours
Cortisol*	72 hours

\* every cycle for the first 24 weeks, then every other cycle.

**Patients should be monitored for up to 5 months after last dose for adverse reactions.**

### Standard limits for administration to go ahead

If blood results not within range, authorisation to administer **must** be given by prescriber/ consultant.

Investigation	Limit
Neutrophil count	$\geq 1.0 \times 10^9/L$
Platelets	$\geq 75 \times 10^9/L$
Creatinine Clearance (CrCl)	$\geq 30\text{mL}/\text{min}$
Bilirubin	$\leq 1.5 \times \text{ULN}$
ALT/AST	$< \text{ULN}$
Alkaline Phosphatase	$< 5 \times \text{ULN}$

### Dose modifications

Dose reductions are not recommended. Doses should be delayed until an adverse reaction resolves to  $\leq$  grade 1.

### Toxicity

Immune related toxicities may affect any organ system and should be considered for any new symptoms. Grade 1 toxicities should be managed symptomatically with close monitoring. Specific management guidelines for immune-related adverse reactions are described in full in the summary of product characteristics for Nivolumab.

- **Haematological toxicity**

Discuss with the consultant if:

WBC  $< 2.0 \times 10^9/L$

Neutrophils  $< 1.0 \times 10^9/L$

Platelets  $< 75 \times 10^9/L$

- **Renal impairment**

No dose modifications required in mild-moderate renal impairment. Use with caution in severe renal impairment.

- **Hepatic impairment**

Nivolumab has not been studied in moderate to severe hepatic impairment. Use with caution if bilirubin > 1.5 x ULN – consultant decision.

- **Other toxicities**

**Severe pneumonitis and interstitial lung disease**

Severe pneumonitis or interstitial lung disease, including fatal cases, have been observed with nivolumab monotherapy. Patients should be monitored for signs and symptoms of pneumonitis including radiographic changes, dyspnoea, and hypoxia. Infectious and disease-related causes should be ruled out.

Grade 2 pneumonitis: withhold treatment, initiate corticosteroids (equivalent to 1mg/kg/day methylprednisolone). Once improved taper steroids slowly over 1 month, treatment may be recommenced when toxicity settled to grade 1 or less.

≥ Grade 3 pneumonitis: permanently discontinue treatment admit and initiate intravenous corticosteroids (equivalent to 2-4mg/kg/day methylprednisolone). Discuss with consultant. If doses > 2mg/kg/day methylprednisolone are required consider alternative immunosuppressive agents.

**Immune-related adverse reactions**

Immune-related adverse reactions can be severe or life-threatening and may involve the gastrointestinal, liver, skin, nervous, endocrine, or other organ systems. While most immune-related adverse reactions reported occurred during the induction period, onset months after the last dose have also been reported. Unless an alternate aetiology has been identified, diarrhoea, increased stool frequency, bloody stool, LFT elevations, rash and endocrinopathy must be considered inflammatory and treatment-related. Early diagnosis and appropriate management are essential to minimise life-threatening complications.

Systemic high-dose corticosteroid with or without additional immunosuppressive therapy may be required for management of severe immune-related adverse reactions. Specific management guidelines for immune-related adverse reactions are described in full in the summary of product characteristics for nivolumab.

Management of immune-related adverse reactions may require a dose delay or permanent discontinuation of treatment and initiation of systemic high-dose corticosteroid or, in some cases, the addition of other immunosuppressive therapy. Dose reduction is not recommended.

**Permanently discontinue treatment in patients with the following symptoms:**

Management of these reactions require high dose systemic corticosteroid therapy: Admit for intravenous corticosteroids (equivalent to 2-4mg/kg/day methylprednisolone) and discuss with consultant.

Toxicity – severe or life threatening	Definition
Gastrointestinal	Grade 4 diarrhoea/colitis
Hepatic	Grade 3-4 elevation in AST/ALT and/or bilirubin
Nephritis/renal dysfunction	Grade 4 elevation in serum creatinine
Skin	Grade 4 rash Grade 3 pruritus
Endocrine	Grade 4 hypothyroidism Grade 4 hyperthyroidism Grade 4 hypophysitis Grade 3-4 adrenal insufficiency Grade 4 diabetes
Neurological	Grade 3 or 4 motor or sensory neuropathy
Pneumonitis	Grade 3 or 4 pneumonitis
Other	Grade 4 Recurrent grade 3 Persistent grade 2-3 despite treatment modification; inability to reduce corticosteroid dose to 10mg prednisolone/day (or equivalent)

**Withhold treatment in patients with the following symptoms:**

Initiate oral corticosteroids (equivalent to 1mg/kg/day methylprednisolone). Once improved taper steroids slowly over 1 month, treatment may be recommenced when toxicity settled to grade 1 or less.

Toxicity	Definition
Gastrointestinal	Grade 2-3 diarrhoea/colitis
Hepatic	Grade 2 elevation in AST/ALT and or bilirubin
Nephritis/renal dysfunction	Grade 2-3 elevation in serum creatinine
Skin	Grade 3 rash
Endocrine	Symptomatic grade 2-3 hypothyroidism Symptomatic grade 2-3 hyperthyroidism Symptomatic grade 2-3 hypophysitis Grade 2 adrenal insufficiency Grade 3 diabetes
Neurological	Grade 2 motor or sensory neuropathy
Pneumonitis	Grade 2 pneumonitis
Other	Grade 3 (first occurrence)

**Adverse effects - for full details consult product literature/ reference texts**

- **Serious side effects**

Immune reactions may occur during or after completion of treatment.

Colitis

Hepatitis

Peripheral neuropathy

Hypopituitarism

Hypothyroidism

Uveitis

Glomerulonephritis

Cardiac events

Thromboembolism

Interstitial lung disease

- **Frequently occurring side effects**

Pruritus  
Rash  
Nausea and vomiting  
Diarrhoea  
Fatigue  
Decreased appetite  
Hyperglycaemia  
Abdominal pain  
Anorexia

- **Other side effects**

Tumour pain  
Headache  
Raised transaminases

**Significant drug interactions** – for full details consult product literature/ reference texts

**Anticoagulants:** increased risk of haemorrhage – avoid or closely monitor.

**Corticosteroids:** use of systemic corticosteroids at baseline, before starting nivolumab, should be avoided because of their potential interference with the pharmacodynamic activity and efficacy of the agent. However, systemic corticosteroids or other immunosuppressants can be used after starting nivolumab to treat immune-related adverse reactions.

**Additional comments**

The prescriber must discuss the risks of nivolumab therapy with the patient and provide the Patient Alert Card.

All patients on high dose prolonged corticosteroids should be warned about the risk of steroid induced NIDDM.

**Contraception:** Adequate methods of contraception should be used during therapy and for 8 weeks after last dose.

---

**References**

- National Institute for Health and Clinical Excellence TA483. Accessed 29 August 2018 via [www.nice.org.uk](http://www.nice.org.uk)
- Summary of Product Characteristics Nivolumab (Bristol Myers Squibb) accessed 29 August 2018 via [www.medicines.org.uk](http://www.medicines.org.uk)
- Brahmer J, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. NEJM. 2015. 373(2): 123-135

---

Written/reviewed by: Dr A Cox (Consultant Oncologist, RUH Bath NHS Trust)

Checked by: Sarah Murdoch (Senior Oncology Pharmacist, SW Clinical Network)

Authorised by: Dr J Braybrooke (Consultant Oncologist, UHBristol NHS Trust, SW Clinical Network)

Date: November 2018

---